Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 8/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20644432 | 0.84 | KMT2A (0.58) | IDO1ALDH1A1TDP1L3MBTL1KMT2A | |
| SCHEMBL10066809 | 0.83 | IDO1 (0.63) | IDO1ALDH1A1TDP1MAPK1L3MBTL1 | |
| SCHEMBL19473645 | 0.83 | IDO1 (0.63) | IDO1ALDH1A1L3MBTL1KMT2ANOS3 | |
| SCHEMBL24678431 | 0.83 | ALDH1A1 (0.58) | IDO1ALDH1A1TDP1MAPK1L3MBTL1 | |
| SCHEMBL16348281 | 0.83 | ALDH1A1 (0.53) | IDO1ALDH1A1TDP1MAPK1L3MBTL1 | |
| SCHEMBL30311836 | 0.82 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL7081788 | 0.82 | IDO1 (0.61) | IDO1TDP1L3MBTL1NOS3NOS1 | |
| SCHEMBL9646712 | 0.82 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL8345818 | 0.81 | IDO1 (0.50) | IDO1ALDH1A1TDP1L3MBTL1KMT2A | |
| SCHEMBL8310153 | 0.80 | ALDH1A1 (0.55) | IDO1ALDH1A1TDP1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114765987-B | Heat and UV curable adhesive composition | 汉高股份有限及两合公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20240376133-A9 | CROSSLINKING COMONOMERS FOR HIGH PERFORMANCE DEGRADABLE THERMOSETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-11-14 | — | — | US | disclosed |
| EP-4396354-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024145435-A2 | LIPID COMPOSITIONS AND METHODS FOR DELIVERY TO IMMUNE CELLS | Life Technologies Corporation (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024130217-A1 | STAPLED PEPTIDES AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024130218-A1 | STAPLED PEPTIDES AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-4355350-A1 | STAPLED PEPTIDES AND METHODS THEREOF | Fog Pharmaceuticals, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20230416283-A1 | CROSSLINKING COMONOMERS FOR HIGH PERFORMANCE DEGRADABLE THERMOSETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-12-28 | — | — | US | disclosed |
| WO-2023250342-A2 | CYCLOPROPENE PHOSPHORAMIDITES AND CONJUGATES THEREOF | Quantum-Si Incorporated (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-4288110-A2 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | Biohaven Therapeutics Ltd. (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2018223056-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-12-06 | — | — | WO | disclosed |
| EP-3297675-A1 | 5-ALA DERIVATIVES AND USE THEREOF | Université de Genève (CH) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016185368-A1 | 5-ALA DERIVATIVES AND USE THEREOF | UNIVERSITE DE GENEVE (CH) | 2016-11-24 | — | — | WO | disclosed |
| EP-2970184-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATON OF HEMOGLOBIN | Global Blood Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2958895-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | Kala Pharmaceuticals, Inc. (US) | 2015-12-30 | — | — | EP | disclosed |
| WO-2014150261-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATON OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014130612-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| EP-2404912-A2 | Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds | Pharma Mar S.A. (ES) | 2012-01-11 | — | — | EP | disclosed |
| EP-1951656-A1 | HISTONE DEACETYLASE INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISEASES | The Scripps Research Institute (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007058927-A1 | HISTONE DEACETYLASE INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376133-A9 | CROSSLINKING COMONOMERS FOR HIGH PERFORMANCE DEGRADABLE THERMOSETS | PGD, CDCA2, MCM2 | IDO1 530/4885ALDH1A1 625/4885TDP1 87/4885 |
| US-20230416283-A1 | CROSSLINKING COMONOMERS FOR HIGH PERFORMANCE DEGRADABLE THERMOSETS | PGD, CDCA2, MCM2 | IDO1 530/4885ALDH1A1 625/4885TDP1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.